Author

W. Saso

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 2 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

H. Ohashi· 3 shared K. Kuramochi· 3 shared K. Watashi· 3 shared M. Muramatsu· 3 shared M. Takeda· 3 shared T. Suzuki· 3 shared T. Wakita· 3 shared K. Shionoya· 2 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

H. Ohashi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Identification of anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) oxysterol derivatives in vitro

H. Ohashi, F. Wang, F. Stappenbeck, K. Tsuchimoto, C. Kobayashi, W. Saso, M. Kataoka, K. Kuramochi, M. Muramatsu, T. Suzuki, C. Sureau, M. Takeda, T. Wakita, F. Parhami, K. Watashi

This study identifies oxysterol derivatives with anti-SARS-CoV-2 activity, showing that Oxy210 and Oxy232 inhibit viral replication by disrupting double membrane vesicles.

bioRxiv · Jan 31, 2021Microbiology

Anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) potency of Mefloquine as an entry inhibitor in vitro

K. Shionoya, M. Yamasaki, S. Iwanami, Y. Ito, S. Fukushi, H. Ohashi, W. Saso, T. Tanaka, S. Aoki, K. Kuramochi, S. Iwami, Y. Takahashi, T. Suzuki, M. Muramatsu, M. Takeda, , K. Watashi

This study identifies Mefloquine as a potent in vitro entry inhibitor of SARS-CoV-2 with higher antiviral activity than Hydroxychloroquine.

bioRxiv · Nov 19, 2020Microbiology

Multidrug treatment with nelfinavir and cepharanthine against COVID-19

H. Ohashi, K. Watashi, W. Saso, K. Shionoya, S. Iwanami, T. Hirokawa, T. Shirai, S. Kanaya, Y. Ito, K. S. Kim, K. Nishioka, S. Ando, K. Ejima, Y. Koizumi, T. Tanaka, , T. Wakita

This study identifies a new multidrug combination treatment for COVID-19 using nelfinavir and cepharanthine, showing synergistic antiviral effects and improved disease control.

bioRxiv · Apr 14, 2020 · PreprintMicrobiology